Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I thought so at $5.75 but wanted to ease in. I think there are both buyers and shorts covering at this level. The CEO made a few large open market purchases the end of Dec.
Lot's of promise here with Pie Five.
Hmm, that's not really true. In 2011 it reached it's high point in Dec. In 2012 it reached is low point in June. In 2013 it reached it's high point in Nov. In 2014 high point was August. In 2015 high point was March.
Guess you don't look at charts. Must be a swing trader.
Got my starter block around 5.70 a share.
Will look to add on dips or as it starts to move up. I'm guessing shorts are closing out their positions for 2015.
Looking to buy.
I've done most of my homework and I'm going to place a buy order. Glad I found it after the big price drops.
Making a list, checking it twice. Who wants to make the case for this one being up say 50% by this time next year?
Try being more specific. You and Pascoe.
What section in the 10k speaks to my last post?
I usually skip thru the CEO comments on a quarterly call and hit the Q&A first. It's the only non-scripted info you'll get and can tell you a lot more about the future (and details not offered about the past).
The continued problem with APRI calls is analysts can't forecast revenue/royalties. Quote "So over time, we do expect revenues as well as associated royalties to grow". Not helpful. Not specific.
Other Q&A quotes of interest. "I would say that the majority of the sales that occurred in 2014 went towards the stocking of those launches....." and "obviously when one is in a launch phase with any product, there is situations that will arise where we have to make certain concessions or considerations to partners on the transfer price".
It's still not clear to me how much product has been bought by patients. So unlike others here, I believe the reason for the recent downtrend in PPS is the continued uncertainty around purchases being made by patients, not partners. You can talk all you want about partners and launches (yes, they are important), but critical to the longevity of APRI is repeated use by patients.
And if investors believed you when you were screaming "buy it" when it was around $2.20 a share they would still be down.
All you needed to do was keep saying it and sooner or later you would be right.
Let's see what the next CC does to the PPS.
What were the directions? Also, how much were 4 plus shipping?
Thanks.
Well, I'm not drinking the $5 kool-aid yet. At least not in 2015.
While I believe the company is clearly now a better speculative buy than early 2014 (when I first found it), I'm still waiting for Vitaros milestone/royalty payments and fresh financials. "Rx growth continues to exceed our expectations".....and what were those again? Oh, we don't know them. Hmmm. What we do know is Apicus Mgt expects payments to offset operating expenses.
The pipeline? Basically it's move Fispemifene and RayVa trials along. This is to be expected but don't expect any revenues here for years.
Some have tried to argue Vitaros doesn't matter. I disagree and I think Apricus Mgt would also disagree with this notion. It doesn't have to be a blockbuster, but it needs to help pay the bills. And, as some have pointed out, maybe something can happen in North America.
I say we still don't know enough to place lofty PPS numbers on this stock. Let's see what we know after 2 earnings conference calls.
Ok, Ok, even I'm coming around. Getting $11M @1.82 given the recent run-up is impressive. That's means others are impressed with MANAGEMENT (there, i said it) and where the company is headed.
For the record, I did pick up extra shares at 1.45 back a few weeks ago. I don't hold anywhere near what I had before but I like my entry.
I'm waiting for more royalty data and launches before I add. Any weak data could mean PPS goes south again in the short run (even if the future appears better).
LOL, you are quite funny. Make money, lose money. I have no feelings either way unless you spread it around in my direction.
I'll ignore the personal remarks (a trademark of your posts in general) and stay on topic.
This is about CEO compensation tied to company performance. Financials and PPS. While it appears APRI made progress organizationally in 2014, shareholders got red ink. And Pascoe got paid. Wrong message.
End of story.
The only cop out I can see is the Board giving RP a $170,000+ bonus when the PPS went from $2.49 to $1.00. Only a blind investor would give a pass on this.
While I agree with most of the organizational moves in 2014, this does not warrant a 50% bonus. Why don't you use your APRI profits and send him the 3x since you're so pleased?
I've sent an inquiry to APRI IR and asked the question from my last post (which you conveniently ignored). What achieved goals or metrics warranted a 50% bonus?
Let's see if they respond. I doubt it.
LOL, sure. Triple it. He won't be getting any flowers or chocolates from me.
I want my CEOs to create more shareholder value as it relates to financials and stock price. If they don't in a given year, then no/small bonus. Same with the rest of the Board and executives.
Exactly what goals and metrics did he achieve to deserve a 50% bonus?
$170,625.
That's RP's bonus for 2014. Well, it's clear his bonus wasn't tied to stock performance.
I was thinking about adding shares but that number gave me pause.
New Buyer. Long for now.
S&P projects revenue growth of 30%+, .54 EPS. PT of $31. Current fair value of $16.03.
Given the bounce off $15ish, this heads above $20 for 2015. The party is over (at least for now) with those betting on lower PPS.
Well, it is after all, just a couple of days. But seeing my APRI buys in the green is a nice change. And I have no regrets selling the bulk of my holdings months ago as my buys have performed well in general.
Given the Mo, it will probably go higher. The question is, when they report, what will be the news? And why haven't there been additional launches (if product sales "exceed expectations")?
Look out. I'm only down 4% on my 700 shares.
I think in general this is very good advice.
However, I have examples of where it has worked out for me in the long run. Apple for one. If you pick right company to own, the market will get it right over time.
When it comes to stocks like APRI, a clear speculative pick, it's anyones guess where it is headed.
We haven't agreed much recently SB but we are on the same page with this one. Most of those "execs" should have been shown the door months ago. And I hope most or all of their options are underwater.
I'm going to add to my position in January once I add to my Roth.
Rock bottom in terms of 52 week high/lows. The market is saying it's not rock bottom from a short term perspective (maybe LT) value.
Better read this post by 3:30 CT or it gets deleted.
It's because, Tom, this one is a turkey. Most still believe it could come a golden goose.
Me, I've upped my share count to 500 now. And that's all this one deserves in my Roth.
Excellent find js.
I'm keeping a small amount of shares in my Roth. As long as I own something I track it.
Bottom fishing. Added 100 shares at $1.34.
I posted a response but it got deleted. So it goes on the ihub.
With less than 8% institutional ownership it's safe to say interest is low. That's a current fact.
Relative strength is less than 15. That's a fact.
Since the earning call on Monday, the stock has gone backwards. That's a fact.
Dead money.
Maybe. I think PLNR projected very conservative guidance for Q1.
I hope weak hands buy this rating so I can get cheaper shares. I'd like to load up in the lower $6 range (better if the market gets negative and drives it down).
Of course what you are saying SB is price targets don't mean anything. From anybody. I'm fine with that.
But all of you wanting institutional buying then are wasting your time if analysts can't crunch numbers. And institutions drive stock price.
I said this was dead money for now. And now you know why.
Well, you might be missing a financial model which actually supports a $4 PO. A typical model contains revenue, income, and cash flows. Didn't see that in this brief. That's why analysts press APRI management for details. They are trying to build a reliable model so they can create a PO.
I'm guessing you are long the stock? I didn't see a disclosure.
Yes, I have strong opinions. And, I do my best to support them with facts and/or references. There is usually a shortage of that on stock blogs.
Unlike a bull or a bear, a short or a long, I'm not interested in the APRI spin. Spun by anyone on the this board or by APRI Mgt. Just because someone believes something doesn't make it so. We all know that one.
For me, 300 shares keeps this investment real. And some incentive to post and stir things up a bit.
One thing is for sure. You're not paying your bar tab with APRI profits.
IR "And then going forward you’re going to sort of be very clean and transparent in how you report the different buckets of revenue just so we can back into everything"?
This question tells you why this stock is dead money until APRI gives analysts and shareholders .....
(wait for it)
Ah yes. DETAILS.
Rob says "it would follow that it would be borderline unethical to call those "strong sales".
Pascoe says "initial sales figures are tracking well above our partner's forecast."
GTP: This all means nothing. No details. What forecast?
Rob: "You do understand under the terms of the agreements, their partners bare the brunt of the financial burden of bringing the drug to market. Why would they ever do that if it was a dud?"
GTP: Well, they have to keep giving out free samples and pushing product because they did make up front payments. Too early to tell if it is a dud or not. But they could, at some point, give up on it (my guess is this has happened before).
Rob: "only after said date would they be able to pay out any sales royalties to entitled parties..."
GTP: Maybe. What are the invoice and payment arrangements? Just another missing detail.
You can call it good news. I'll just call it news.
scooty, nice summary.
Given the lackluster report (no surprise) , I'm not adding here (if at all). This stock goes lower before it goes higher. Much more pain before any gain.
I've said this before, and I'll say it again. The opportunity cost for being in this stock is off the charts. I'm glad I've moved on (except for 300 shares).
Just another short term trader wrong about a stock.
Yawn.
I think you're off the range cowboy. This is a LTBH stock.
Head back to the traders range.
Don't forget to check your crystal ball.
And while you're at it, do the simple forward p/e math. It says this stock should be around $9 this time next year.
If goes down 30% (I hope), I'm a buyer.
If you think so, go for it.
But it didn't just go up on blowout earnings and rising revenues. Suggest you do your homework. But then again, shorts aren't known for doing homework.
Hey, $10 by EOY.
You got it. Remember the last call?
"exceeded our initial expectations with their launch of Vitaros in the United Kingdom, as evidenced by the additional commercial orders that Takeda has placed with us for our product".
Hey RP, what were those expectations again? And how many orders?
"Moreover, the feedback from patients and physicians has been positive...."
Yeah, what informal/formal feedback system do you have? How was this collected and the data organized?
"We believe that Vitaros, which is an approved product in Canada, is commercially viable in its current form, and as such, could be launched in Canada".
Watch for that "We believe" phrase in the future. Trouble ahead.
"While we have made progress in our efforts to out-license Femprox, our process is still ongoing..."
Yeah, exactly what kind of progress was that back then? You got return calls that said "Thanks, no thanks?"
Now that I did this review, I wondering if I have too much APRI stock in my Roth IRA.
Well, I see my 300 shares are now in a very familiar place. Red.
Let's see what DETAILS we get (or don't get) next week. It will tell me IF I should double up or dump.
Thanks for this stocktrademan.
I just listened to the conference call. Now this is a GROWTH company. They are going to put up some big YoY numbers next year.
I'm long the stock as of just a few weeks ago. Good timing for me.